FDA Hears Concerns About The Unregulated CBD Market

  • Forbes | by: Holly Lawrence |
  • 06/04/2019 12:00 AM
A Call for Regulatory Oversight

The FDA hearing’s first speaker, Peter Pitts, president of the Center for Medicine in the Public Interest and a former FDA associate commissioner, set the theme. “The absence to date, of advanced regulatory thinking relative to CBD has resulted in a maelstrom of false claims and shoddy quality standards,” Pitts said.

He called out “aggressive and misleading marketing campaigns” for CBD products, and urged, “It’s time for the proponents of CBD, including many highly vocal patients, physicians, pharmacists, manufacturers and distributors, to become part of the solution.

“Quality must always trump corporate convenience,” Pitts said, expressing the need for production quality oversight.

He also described a lack of a dosing schedule for CBD products. “When people are told to use CBD by physicians, pharmacists, friends or internet experts, they are not given any peer-reviewed guidelines on how they should take it or in what amounts — something that should never happen,” Pitts said.

 
Sign Up for Our Email Newsletter

RECENT NEWS

Peter Pitts speaks to CNN about baby formula shortage
  • CNN
  • 05/13/2022 12:00 AM

Peter Pitts speaks to CNN about baby formula shortage

Former FDA Associate Commissioner Peter Pitts speaks with CNN on the shortage of baby formula on May 13, 2022....  Read more

Peter Pitts on the reported upcoming FDA ban on Juul with News Nation

Peter Pitts on the reported upcoming FDA ban on Juul with News Nation

Peter Pitts discusses a potential FDA ban on Juul with News Nation...  Read more

Peter Pitts joins NewsNation to discuss Abbott and the baby formula shortage

Peter Pitts joins NewsNation to discuss Abbott and the baby formula shortage

Peter Pitts, a former FDA Associate Commissioner, speaks about the baby formula shortage on News Nation...  Read more

DRUGWONKS BLOG